ALTB-268

Therapeutic Area

Product Overview
Inheriting the unique mechanism of action from ALTB-168, ALTB-268 is subtly designed as a tetravalent molecule to achieve better efficacy. From preclinical and phase 1 clinical studies ALTB-268 exhibits not only comparable safety profiles, but also improved potency in down-regulating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equivalent efficacy in clinical is expected.

Indication

Ulcerative Colitis

1

  • PRECLINICAL

  • PHASE I

  • PHASE IIA

    Phase II

  • PHASE IIB

  • PHASE III

Introduction

Based on the structure of ALTB-168, ALTB-268, a second generation antibody with tetravalent design that leads to improved potency, is under development. In vitro and in vivo studies with ALTB-268 have demonstrated a potentially 10-fold increase in activity of down-regulating late-stage, chronically activated T cells (immune cells that cause inflammation) as compared with ALTB-168.

The company is dedicated to bringing forth ALTB-268 into the clinic, currently in a Phase 2a trial with ulcerative colitis patients. Additional autoimmune indications will be explored based on solid signs of clinical efficacy demonstrated with ALTB-168.

More